Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer

The research group on adaptive image-guided radiotherapy for locally advanced cervical carcinoma completed the protocol for the EMBRACE II study in October 2018. This study will be carried out in the next few years at the University Clinic for Radiotherapy at the Medical University of Vienna and other international partner institutes. EMBRACE II builds on the findings of the current EMBRACE study. These are already implemented in everyday clinical practice in order to further improve the accuracy of the entire therapy of cervical carcinomas, using state-of-the-art techniques of tele- and brachytherapy. The aim of the EMBRACE II study is to maintain and enhance the excellent local tumor control as well as the nodal and systemic control for all tumor stages while minimizing the adverse reaction rates for all affected organs (rectum, sigmoid, urinary bladder, and vagina) to increase the quality of life of patients with cervical carcinomas.

NCT Number	NCT03617133
Lead Sponsor	Medical University of Vienna Collaborators: Universitaire Ziekenhuizen KU Leuven, Aarhus University Hospital, Rigshospitalet, Denmark, Odense University Hospital, North Estonia Medical Centre, Institut Bergonié, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital Heidelberg, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Oslo University Hospital, Institute of Oncology Ljubljana, Complejo Hospitalario de Navarra, Hospital Clinic of Barcelona, Skane University Hospital, Region Örebro County, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radiotherapiegroep, Leiden University Medical Center, Maastro Clinic, The Netherlands, UMC Utrecht, The Netherlands Cancer Institute, Radboud University Medical Center, Catharina Ziekenhuis Eindhoven, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, The Christie NHS Foundation Trust, University Hospitals Coventry and Warwickshire NHS Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Cross Cancer Institute, McGill University, Princess Margaret Hospital, Canada, Tom Baker Cancer Centre, Loyola University Chicago, M.D. Anderson Cancer Center, University of Pittsburgh, Pamela Youde Nethersole Eastern Hospital, Tuen Mun Hospital, Post Graduate Institute of Medical Education and Research, Chandigarh, Tata Memorial Centre, Chulalongkorn University, Siriraj Hospital, Liverpool Hospital, Sydney, Maisonneuve-Rosemont Hospital, National Cancer Institute, Slovakia, Institut Català d'Oncologia, Ludwig-Maximilians - University of Munich, Mount Vernon Cancer Centre, St Thomas' Hospital, London
Conditions	Uterine Cervical Neoplasms
Enrollment	1,000 participants
Start Date	2016-04
Primary Completion	2021-12-31 (estimated)
Study Completion	2031-04 (estimated)
Updated on ClinicalTrials.gov	2022-03-17